Allogene Therapeutics
Price & Volume
Stats
See moreOpen | $1.43 |
Previous Close | $1.42 |
Day Range | $1.43-$1.47 |
52W Range | $0.86-$3.78 |
Market Cap | $319.1M |
Shares Short | 18M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | -100% |
Gross Profit (12 Mos) | -$166.4M |
Diluted EPS | -$0.98 |
News
See moreYahoo Finance • 16 days ago
November 2025's Promising Penny Stocks To Watch
Yahoo Finance • 22 days ago
Allogene signals pivotal ALPHA3 interim data and ALLO-329 proof-of-concept in first half 2026 while maintaining cash runway into H2 2027
Yahoo Finance • 22 days ago
Here are the major earnings after the close Thursday
Yahoo Finance • 25 days ago
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
About
CEO | Dr. David D. Chang M.D., Ph.D. |
CFO | Mr. Geoffrey M. Parker |
Address | 210 East Grand Avenue, South San Francisco, CA, United States, 94080 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 226 |
